title: Anti-Thrombotic Effects of Statins in Acute Coronary Syndromes: At the Intersection of Thrombosis, Inflammation, and Platelet-Leukocyte Interactions.
abstract: HMG CoA reductase inhibitors, or statins, are standard of care for preventing cardiovascular disease in at-risk populations. Statins are a well-established therapy proven to reduce long-term cardiovascular mortality and morbidity for prevention of secondary cardiovascular events and have become guidelinerecommended therapy following acute myocardial infarction. Emerging data from clinical trials over the last decade indicates that statin therapy may provide broad beneficial effects beyond their primary lipid lowering mechanisms. In coronary heart disease, statins have demonstrated a unique ability to target several cellular pathways, which appear to play an underappreciated role in acute inflammation and subsequent thrombosis. Herein, we review the potential mechanisms where statins may act as antithrombotic agents in the setting of acute coronary syndromes and discuss the clinical implications of these findings.
authors.affiliation: Division of Cardiovascular Medicine, The Gill Heart Institute, 255 BBRSB, 741 S. Limestone Street, Lexington, KY 40536-0200, United States. trsext2@uky.edu.
authors.forename: Travis
authors.initials: T
authors.lastname: Sexton
authors.forename: Eric L
authors.initials: EL
authors.lastname: Wallace
authors.forename: Susan S
authors.initials: SS
authors.lastname: Smyth
mesh_terms: D054058:Acute Coronary Syndrome / Q000188:drug therapy* / Q000503:physiopathology; D001792:Blood Platelets / Q000187:drug effects / Q000502:physiology; D002450:Cell Communication; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D007249:Inflammation / Q000188:drug therapy; D007962:Leukocytes / Q000502:physiology; D009203:Myocardial Infarction / Q000188:drug therapy; D062645:Percutaneous Coronary Intervention; D013927:Thrombosis / Q000517:prevention & control*
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors